Semnur Pharmaceuticals, Inc. SMNR
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 5,328.21% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 3,101.53% | -- |
| Operating Income | -- | -- | -- | -3,101.53% | -- |
| Income Before Tax | -- | -- | -- | -3,101.53% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -3,101.53% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -3,101.53% | -- |
| EBIT | -- | -- | -- | -3,101.53% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | -- | -2,588.11% | -- |
| Normalized Basic EPS | -- | -- | -- | -2,584.36% | -- |
| EPS Diluted | -- | -- | -- | -2,588.11% | -- |
| Normalized Diluted EPS | -- | -- | -- | -2,584.36% | -- |
| Average Basic Shares Outstanding | -- | -- | -- | 17.90% | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | 17.90% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |